跳至主要内容
临床试验/CTRI/2010/091/001185
CTRI/2010/091/001185已完成未知

Developing and Testing Integrated, Multi-factorial Cardiovascular Disease Risk Reduction Strategies in South Asia (CARRS Translation Trial)

ational Heart Lung and Blood Institute National Institutes for Heath USA0 个研究点目标入组 1,146 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
1,146

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Age 35 years and older
  • 2. Confirmed diagnosis of diabetes based on documented evidence from oral glucose tolerance test or two venous fasting blood sugar levels or known diabetes patient on medication or insulin
  • 3. Poor glycemic control (as evidenced by HbA1c greater than or equal to 8.0%) AND one or both of: dyslipidemia (LDL greater than or equal to 130 mg/dl) or systolic hypertension (SBP greater than or equal to 140 mmHg), irrespective of lipid- or BP-lowering medication use, respectively
  • 4. Receiving diabetes care in the same clinic for at least 3 months OR even earlier if in the investigators assessment the patient is likely to follow-up regularly as required by the protocol.
  • 5. Willingness to consent to randomization
  • Note- The trial has no upper age limit.

排除标准

  • Individuals will be excluded from participation if any of the following are present during screening:
  • 1. Known type 1 diabetes mellitus
  • 2. Diabetes secondary to chronic pancreatitis
  • 3. Pregnant OR trying to become pregnant OR of child-bearing potential and not actively practicing birth
  • control (including natural methods)
  • 4. Evidence of pre-existing well-controlled blood glucose, blood pressure or LDL-cholesterol (as
  • evidenced by HbA1c < 7.0%, SBP < 130 mmHg, LDL-cholesterol < 100 mg/dl [LDL-cholesterol < 70
  • mg/dl with history of CVD event]) obtained from screening within a period not exceeding 28 days (4
  • weeks) prior to randomization
  • 5. Documented cardiovascular event (coronary revascularization, stroke, MI, unstable angina) in past 12
  • 6. Current symptomatic CHF or NYHA Class 3 or 4 effort intolerance
  • 7. Documented non-diabetic kidney disease OR pre-existing end -stage renal disease (on renal replacement therapy [dialysis or transplant])
  • 8. Transaminase >3 times upper limit of normal OR active liver disease within past 2 years
  • 9. Malignancy or life-threatening disease with death probable in 4 years
  • 10. Any current medication (e.g. long-term steroids, protease inhibitors) that, in the opinion of the site investigator, would interfere with participant?s diabetic status and follow-up
  • 11. Any condition or circumstance that is unrelated to diabetes progression, that in the opinion of the site investigator would interfere with the participant?s diabetic status and follow-up: including (but not limited to) other endocrinopathy [adrenal, pituitary], TB patient on treatment, psychiatric illness or cognitive impairment, alcohol or drug abuse, history of organ transplant, BMI >= 45 kg/m2
  • 12. On an investigational drug in the last 3 months
  • 13. Currently participating in a clinical trial
  • 14. No fixed address or contact details
  • 15. Plans to move in the next 3 years
  • 16. A member of the participant?s household is currently in the trial
  • 17. Inability or unwillingness of individual or legal guardian /representative to give written informed consent

研究者

发起方
ational Heart Lung and Blood Institute National Institutes for Heath USA

相似试验